What's in Jiangsu Alphamab Biopharmaceuticals Co., Ltd's pipeline?

Jiangsu Alphamab Biopharmaceuticals Co., Ltd has 11 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 3 in Phase 2, 5 in Phase 1.

Which companies overlap with Jiangsu Alphamab Biopharmaceuticals Co., Ltd's portfolio?

Top competitors by shared drug class: Jiangsu HengRui Medicine Co., Ltd., Sun Yat-sen University, Fujian Cancer Hospital, Innovent Biologics (Suzhou) Co. Ltd., Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jiangsu-alphamab-biopharmaceuticals-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Jiangsu Alphamab Biopharmaceuticals Co., Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Jiangsu Alphamab Biopharmaceuticals Co., Ltd pipeline: 0 marketed, 0 filed, 3 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 3 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
KN046	KN046	phase 3	Bispecific antibody; PD-L1/4-1BB bispecific immune checkpoint modulator	PD-L1 and 4-1BB	Oncology
JSKN003	JSKN003	phase 3	Bispecific antibody; immune checkpoint inhibitor		Oncology
Eribulin mesylate injection	Eribulin mesylate injection	phase 3	Microtubule inhibitor	Tubulin (microtubule dynamics)	Oncology

Therapeutic area mix

Oncology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
Sun Yat-sen University · 2 shared drug classes
Fujian Cancer Hospital · 2 shared drug classes
Innovent Biologics (Suzhou) Co. Ltd. · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Shanghai Hengrui Pharmaceutical Co., Ltd. · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
mAbxience Research S.L. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu Alphamab Biopharmaceuticals Co., Ltd:

Cite this brief

Drug Landscape (2026). Jiangsu Alphamab Biopharmaceuticals Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-alphamab-biopharmaceuticals-co-ltd. Accessed 2026-05-16.